BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25611264)

  • 21. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
    Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
    Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increasing 14-3-3 sigma expression with declining estrogen receptor alpha and estrogen-responsive finger protein expression defines malignant progression of endometrial carcinoma.
    Nakayama H; Sano T; Motegi A; Oyama T; Nakajima T
    Pathol Int; 2005 Nov; 55(11):707-15. PubMed ID: 16271083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD44 variant 6 in endometrioid carcinoma of the uterus: its expression in the adenocarcinoma component is an independent prognostic marker.
    Hoshimoto K; Yamauchi N; Takazawa Y; Onda T; Taketani Y; Fukayama M
    Pathol Res Pract; 2003; 199(2):71-7. PubMed ID: 12747468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
    Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
    Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morphological, imaging and surgical aspects in endometrial endometrioid adenocarcinoma.
    Berceanu C; Stepan AE; MehedinŢu C; Cîrstoiu MM; Ciortea R; Berceanu S; Gheonea IA; Brătilă E
    Rom J Morphol Embryol; 2016; 57(3):995-1002. PubMed ID: 28002515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
    Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
    Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study, pre-operative recognition of high risk endometrial carcinoma: a multicentre prospective cohort study.
    Visser NC; Bulten J; van der Wurff AA; Boss EA; Bronkhorst CM; Feijen HW; Haartsen JE; van Herk HA; de Kievit IM; Klinkhamer PJ; Pijlman BM; Snijders MP; Vandenput I; Vos MC; de Wit PE; van de Poll-Franse LV; Massuger LF; Pijnenborg JM
    BMC Cancer; 2015 Jun; 15():487. PubMed ID: 26123742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
    Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
    Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical expression of PTEN and beta-catenin for endometrial intraepithelial neoplasia in Japanese women.
    Norimatsu Y; Moriya T; Kobayashi TK; Sakurai T; Shimizu K; Tsukayama C; Ohno E
    Ann Diagn Pathol; 2007 Apr; 11(2):103-8. PubMed ID: 17349568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
    Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
    Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
    Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
    Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. bcl-2 and p53 in endometrial adenocarcinoma.
    Taskin M; Lallas TA; Barber HR; Shevchuk MM
    Mod Pathol; 1997 Jul; 10(7):728-34. PubMed ID: 9237185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin.
    Saad RS; Mashhour M; Noftech-Mozes S; Ismiil N; Dubé V; Ghorab Z; Faragalla H; Khalifa MA
    Int J Gynecol Pathol; 2012 Jan; 31(1):57-65. PubMed ID: 22123724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
    Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
    Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical evaluation is not prognostic for recurrence in fully staged high-risk endometrial cancer.
    Fanning J; Brown S; Phibbs G; Kramer T; Zaher A
    Int J Gynecol Cancer; 2002; 12(3):286-9. PubMed ID: 12060450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.
    Bonneterre J; Hutt E; Bosq J; Graham JD; Powell MA; Leblanc E; Fujiwara K; Herzog TJ; Coleman RL; Clarke CL; Gilles EM; Zukiwski AA; Monk BJ
    Gynecol Oncol; 2015 Sep; 138(3):663-7. PubMed ID: 26142884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progressive derailment of cell cycle regulators in endometrial carcinogenesis.
    Horrée N; van Diest PJ; van der Groep P; Sie-Go DM; Heintz AP
    J Clin Pathol; 2008 Jan; 61(1):36-42. PubMed ID: 17483252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
    Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray.
    Dupont J; Wang X; Marshall DS; Leitao M; Hedvat CV; Hummer A; Thaler H; O'Reilly RJ; Soslow RA
    Gynecol Oncol; 2004 Aug; 94(2):449-55. PubMed ID: 15297187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.